Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways

BACKGROUND: Mesothelioma is resistant to conventional treatments and is often defective in p53 pathways. We then examined anti-tumor effects of metformin, an agent for type 2 diabetes, and combinatory effects of metformin and nutlin-3a, an inhibitor for ubiquitin-mediated p53 degradation, on human m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Shimazu, Kengo, Tada, Yuji, Morinaga, Takao, Shingyoji, Masato, Sekine, Ikuo, Shimada, Hideaki, Hiroshima, Kenzo, Namiki, Takao, Tatsumi, Koichiro, Tagawa, Masatoshi
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5414226/
https://ncbi.nlm.nih.gov/pubmed/28464864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3300-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars